In female Sprague Dawley rats, Cevimeline at 27 mg/kg/day for 9 weeks significantly decreased BMI compared with vehicle control (p < 0.05). TC concentration was significantly lower in both the Cevimeline-only group and the OLZ + CEV group compared with control (p < 0.01). In albino rats receiving MTX, oral Cevimeline at 10 mg/kg daily for 9 days was evaluated with the MTX group as the comparison to isolate the compound effect. The MTX + CVM group had a reported Caspase 3 stained-area readout of 31.09 ± 5.90. [2,3]
BMI reduction in female Sprague Dawley rats
Animal study · female Sprague Dawley rats; n = 12/group [2]
Female Sprague Dawley rats received Cevimeline at 27 mg/kg/day for 9 weeks. BMI decreased significantly compared with the vehicle control (p < 0.05).
Conditions shared by the study groups
- Treatment course
- t.i.d.; 9 weeks
- Vehicle
- 0.6 g cookie dough
- Cevimeline 27 mg/kg/day
- Model: female Sprague Dawley rats; n = 12/group
- Reported limits: Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Cevimeline
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.1. Animal Experimental Design (S1, S10); 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S45)
BMI value: BMI value; comparator: vehicle (0.6 g cookie dough without drugs, control) — 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S45)
Cevimeline 27 mg/kg/day · 2. Materials and Methods > 2.1. Animal Experimental Design (S10); 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S45)
Caspase staining in albino rats receiving MTX and Cevimeline
Animal study · albino rats; MTX + CVM group included 25 rats [3]
Albino rats in the MTX + CVM group received oral Cevimeline at 10 mg/kg daily for 9 days, with MTX at 20 mg/kg as another intervention. The reported Caspase 3 stained-area readout was 31.09 ± 5.90 for the MTX + CVM group, with the MTX group serving as the comparison to isolate the compound effect.
Conditions shared by the study groups
- Route
- taken orally
- Treatment course
- daily for 9 days
- Vehicle
- saline
- Cevimeline 10 mg/kg
- Model: albino rats; MTX + CVM group included 25 rats
- Reported limits: Removed after verification: value.
Methods and source locations
Compound reported in the paper: Cevimeline
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > Experimental protocol (S10, S14); Materials and methods > Rat euthanasia and tissue preparation (S16, S21); Results > Caspase 3 immunohistochemical results (S33); Fig. 2 legend (S43); Table 1 legend (S55, S56); Table 1 (T1.r2, T1.r3)
Caspase 3; percentage of stained area: Caspase 3; percentage of stained area; comparator: 25 rats that received 20 mg/kg MTX as a single intraperitoneal dose on day one and were maintained under observation for 9 days — Materials and methods > Rat euthanasia and tissue preparation (S21); Results > Caspase 3 immunohistochemical results (S33); Fig. 2 legend (S43)
Cevimeline 10 mg/kg · Materials and methods > Experimental protocol (S14); Results > Caspase 3 immunohistochemical results (S33)
Lower TC concentration in female Sprague Dawley rats
Animal study · female Sprague Dawley rats; n = 12/group [2]
Female Sprague Dawley rats received Cevimeline at 27 mg/kg/day for 9 weeks. TC concentration was significantly lower in both the Cevimeline-only group and the OLZ + CEV group compared with control (p < 0.01).
Conditions shared by the study groups
- Treatment course
- t.i.d.; 9 weeks
- Vehicle
- 0.6 g cookie dough
- Cevimeline 27 mg/kg/day
- Model: female Sprague Dawley rats; n = 12/group
- Reported limits: Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: Cevimeline
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Materials and Methods > 2.1. Animal Experimental Design (S1, S10); 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S51)
TC concentration: TC concentration; comparator: vehicle (0.6 g cookie dough without drugs, control) — 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S51)
Cevimeline 27 mg/kg/day · 2. Materials and Methods > 2.1. Animal Experimental Design (S10); 3. Results > 3.2. Cevimeline Cotreatment Ameliorates Olanzapine Effects on Lipid Metabolism and Related Hepatic Alk Pathway (S51)